FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine and pharmaceutical industry, namely to a haemostatic sponge. Haemostatic sponge is characterized by that it is obtained on the basis of dry marine collagen, isolated from deep-sea squid, maintained in a solution of formic acid at pH 3–4, mixed with glutaric aldehyde, solution of sodium salt of carboxymethyl cellulose and glycerine in ratio collagen: Na-CMC in wt.% 50:50, 25:75 or 15:85, by lyophilisation.
EFFECT: invention provides more pronounced collagen expression in wound healing and higher haemostatic properties.
1 cl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
TWO-LAYER HAEMOSTATIC SPONGE BASED ON SODIUM SALT OF CARBOXYMETHYL CELLULOSE OF MEDIUM AND HIGH VISCOSITY | 2023 |
|
RU2813980C1 |
METHOD FOR THE PREVENTION OF ADHESIONS DURING ABDOMINAL OPERATIONS UNDER CONDITIONS OF PARENCHYMAL BLEEDING IN AN EXPERIMENT | 2020 |
|
RU2744540C1 |
HAEMOSTATIC AGENT | 2023 |
|
RU2826361C1 |
LOCAL HEMOSTATIC AGENT | 2023 |
|
RU2807892C1 |
METHOD OF POROUS COLLAGEN MATRIX PRODUCTION | 2023 |
|
RU2808686C1 |
COMPOSITION FOR WOUND TREATMENT AND PRODUCTS ON ITS BASIS | 2011 |
|
RU2467767C1 |
METHOD FOR ASSESSING DYNAMICS OF THROMBOSIS WHEN USING HAEMOSTATIC AGENTS | 2023 |
|
RU2824478C1 |
METHOD OF PRODUCING POROUS COLLAGEN MATRIX BASED ON MARINE COLLAGEN USING GLUTARALDEHYDE | 2023 |
|
RU2821401C1 |
COMPOSITION FOR TEMPORARY CONTROL OF BLEEDING | 2023 |
|
RU2819603C1 |
AGENT FOR PYOINFLAMMATORY PROCESSES IN SOFT TISSUES AND MUCOUS MEMBRANES | 2017 |
|
RU2641095C1 |
Authors
Dates
2025-03-11—Published
2023-09-07—Filed